{
    "clinical_study": {
        "@rank": "166674", 
        "arm_group": [
            {
                "arm_group_label": "Parkinson Disease (PD)", 
                "description": "Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause)"
            }, 
            {
                "arm_group_label": "Healthy Controls", 
                "description": "Healthy individuals"
            }
        ], 
        "brief_summary": {
            "textblock": "A cornerstone in PD research is the investigation of neurophysiological changes as potential\n      biomarkers that could help in tracking disease progression and response to therapies.\n      Electroencephalography (EEG) could provide a non-invasive and relatively cheap tool for\n      identification of such biomarkers. In this study we will use high-density\n      electroencephalograph (EEG) recording, in order to develop a platform of biomarkers that\n      could be more sensitive and reliable to disease progression and response to therapeutic\n      intervention than standard clinical measures."
        }, 
        "brief_title": "Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) Signals for Healthy Controls Evoked Response Potential (ERP) Signals for Healthy Controls and Patients With Parkinson Disease", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic\n             criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical\n             features or secondary cause) and HC aged 40-80 years\n\n          2. PD patients Hoehn and Yahr stages I to IVStable PD therapy\n\n        Exclusion Criteria:\n\n          -  In the investigator's opinion, any unstable or clinically significant condition that\n             would impair the participants' ability to comply with study requirements.\n\n          -  Patients or HC with significant psychiatric symptoms or history\n\n          -  BDI score <14\n\n          -  MMSE <25\n\n          -  Treatment with neuroleptics.\n\n          -  For PD patients: Hoehn and Yahr Stage 5\n\n          -  PD Patients with severe dyskinesia or tremor\n\n          -  PD Patients with  atypical Parkinsonism or secondary Parkinsonism\n\n          -  History or evidence of neurological problems: cerebrovascular disease, previous head\n             injury or neurosurgical interventions.\n\n          -  Currently with lice or open wounds on scalp.\n\n          -  Significant sensory deficits, e.g., deafness or blindness\n\n          -  Current drug abuse or alcoholism.\n\n          -  Pregnancy or not using a reliable method of birth control.\n\n          -  Participation in current clinical study or clinical study within 30 days prior to\n             this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "50 patients with idiopathic Parkinson's disease (PD) 50 Healthy controls (HC)"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149498", 
            "org_study_id": "PD-MAG-01"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Parkinson", 
            "EEG", 
            "BNA"
        ], 
        "lastchanged_date": "May 26, 2014", 
        "number_of_groups": "2", 
        "overall_contact": {
            "email": "naama.warmanalaluf@sheba.health.gov.il", 
            "last_name": "Naama Warman Alaluf, Msc", 
            "phone": "972-3-530-4931"
        }, 
        "overall_official": [
            {
                "affiliation": "Sheba Medical Center Israel", 
                "last_name": "Sharon Hassin, Dr.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Sheba Medical center Israel", 
                "last_name": "Oren Cohen, Dr.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The study outcome measure are functional networks of brain activity of PD patients and healthy individuals established based on an analysis of EEG data recorded while study subjects perform ERP tasks", 
            "measure": "Functional networks of brain activity in Idiopathic PD patients and healthy individuals measured using analysis of EEG Event Related Potential", 
            "safety_issue": "No", 
            "time_frame": "2 WEEKS"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149498"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sheba Medical Center", 
            "investigator_full_name": "Dr. Oren Cohen", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Sheba Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dr. Oren Cohen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}